2017 American Transplant Congress » Poster Session B: Antibody Mediated Rejection in Kidney Transplant Recipients II

Date: Sunday, April 30, 2017

Time: 6:00pm-7:00pm

Location: Hall D1

Session Type: Poster Session

Meeting: 2017 American Transplant Congress

6:00pm-7:00pm: A Lower Mean Exposure to Tacrolimus, Not Intra-Patient Variability Is Associated with Chronic Active Antibody Mediated Rejection.

K. Sablik,¹ M. Clahsen–van Groningen,² T. Van Gelder,¹ M. Betjes.¹

6:00pm-7:00pm: Association of Non-HLA Antibodies with Histological Changes of Antibody Mediated Injury in Kidney Transplantation.

N. Leca,¹ I. Gimferrer,² P. Warner,² K. Nelson,² R. Bakthavatsalam,¹ L. Sibulesy,¹ B. Najafian,³ C. Robinson-Cohen,¹ B. Kestenbaum.¹

6:00pm-7:00pm: Biopsies (Bx) of Renal Allografts with Antibody- + Cell-Mediated Rejection (ABMR/CMR) Exhibit Gene Expression Signatures from Both Types of Rejection.

H. Zhang,¹ C. Nast,² J. Doldron,² M. Cheung,² J. Mirocha,³ J. Kahwaji,¹ A. Vo,¹ S. Jordan,¹ M. Toyoda.¹

6:00pm-7:00pm: Bortezomib for Late Antibody-Mediated Rejection After Renal Transplantation: A Single Center Experience of 22 Cases.

J. Choi, J. Jung, S. Chun, S. Shin, Y. Kim, D. Han.

6:00pm-7:00pm: C-C Chemokine Receptor 5 Polymorphisms and Risk of Antibody-Mediated Rejection in Renal Transplantation.

J. Lee,¹ D. Kim,¹ J. Lee,¹ S.-K. Kwon,¹ S. Song,¹ J. Lee,¹ B. Kim,² M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹

6:00pm-7:00pm: C1q+ and IgG3+ De Novo Donor Specific Antibody Are Associated with Allograft Failure in a Multicenter Cohort.

C. Schinstock,¹ M. Everly,² M. Samaniego,³ M. Gandhi,¹ R. Parikh,⁴ V. Sharma,⁴ M. Stegall,¹ D. Dadhania.⁴

6:00pm-7:00pm: Characterization of De Novo Donor-Specific HLA Antibodies and Correlations with C4d+ Antibody-Mediated Rejection of Kidney Transplants.

R. Rajalingam,¹ D. Kopchaliiska,¹ O. Buenaventura,¹ M. Singh,² S. Tomlanovich.²

6:00pm-7:00pm: Clinical and Molecular Significance of Microvascular Inflammation Negative Transplant Glomerulopathy.

M. Lubetzky,¹ N. Hayde,¹ P. O Broin,² Y. Bao,¹ E. Akalin.¹

6:00pm-7:00pm: Development of Transplant Glomerulopathy in Recipients with Antibody Mediated Rejection: Activation of Inflammatory Pathway Through Renal Poly (ADP-Ribose) Polymerase (PARP).

B. Ozdemir,¹ F. Ozdemir,² E. Baskin,² M. Haberal.³

6:00pm-7:00pm: Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes.

A. Babu,^1,2,3 D. Briggs,³ D. Mitchell,¹ N. Krishnan,² R. Higgins,¹ S. Daga.^1,2,4

6:00pm-7:00pm: Donor-Derived Cell-Free DNA Is a Dynamic Biomarker of Active Rejection in Kidney Allografts.

D. Brennan,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ J. Sninsky,⁴ R. Woodward,⁴ J. Yee,⁴ R. Bloom.⁵

6:00pm-7:00pm: Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population.

J. Bromberg,¹ D. Brennan,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Yee,⁴ J. Sninsky,⁴ R. Bloom.⁵

6:00pm-7:00pm: IVIG + Rituximab as Desensitization Agents to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly Hla Sensitized (HS) Awaiting Deceased Donor Kidney Transplantation.

R. Najjar, E. Huang, A. Vo, J. Cho, S. Louis, A. Hang, A. Peng, S. Jordan.

6:00pm-7:00pm: IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-HLA Antibody (Ab), Resulting in Inhibition of Anti-HLA Ab-Mediated NK Cell Activation and Ab-Dependent Cell-Mediated Cytotoxicity (ADCC) in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts).

S. Ge, M. Chu, J. Choi, S. Louie, A. Kang, A. Vo, A. Peng, S. Jordan, M. Toyoda.

6:00pm-7:00pm: Impact of Complement Component 3 Single Nuclear Polymorphisms on Renal Transplant Recipients with Antibody-Mediated Rejection.

Z. Wang, Z. Han, J. Tao, R. Tan, M. Gu.

6:00pm-7:00pm: Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation.

N. Kamar, V. Hajj, I. Ferrandiz, E. Younes, L. Esposito, A. Hébral, A. Del Bello.

6:00pm-7:00pm: Integrative Analysis of ExomeSeq and Gene Expression Data for Identification of Novel Variants Associated with Antibody-Mediated Rejection in Kidney Transplant.

S. Pineda,^1,2 T. Sigdel,² A. Jackson,³ M. Sirota,^1,2 M. Sarwal.²

6:00pm-7:00pm: Low Level Early Onset De Novo DSA's May Not Portend Early Graft Dysfunction in Kidney Transplant Recipients.

M. Abate, Y. Nigatu, B. Ryu, F. Darras, R. Jafrin, H. Suh, C. Estrada, E. Nord.

6:00pm-7:00pm: Microvascular Inflammation at 4 Months Posttransplant Is Associated with Transplant Glomerulopathy at One and Two Years Independent of Rejection and Donor Specific Antibodies.

H. Khamash, G. Mour, L. Archambault, M. Buras, H. Kosiorek, M. Pando, K. Reddy, H. Chakkera, J. Huskey, S. Nair, A. Jaramillo, M. Smith, B. Kaplan, R. Heilman.

6:00pm-7:00pm: Molecular Classifier of Antibody-Mediated Rejection Is a Better Predictor of Histologic Rejection Than a Corresponding Transcript Set and Is Further Improved When Combined with Classifiers of Rejection Syndromes.

K. Famulski, P. Halloran.

6:00pm-7:00pm: Molecular Significance of Peritubular Capillaritis in Early Transplant Kidney Biopsies of Donor-Specific Antibody Negative Patients.

M. Ajaimy, P. O Broin, Y. Bao, E. Akalin.

6:00pm-7:00pm: Non-Donor-Specific Anti-HLA Antibodies Have an Adverse Impact in Kidney Graft Outcomes.

J. Malheiro,¹ S. Tafulo,² L. Dias,¹ L. Martins,¹ I. Beirão,¹ A. Castro-Henriques.¹

6:00pm-7:00pm: Outcome of Systemic Monitoring of DSA and Protocol Management to Optimize Renal Allograft Outcome in a Single Transplant Center.

S. Chang,¹ I. Mallawaarachchi,² C. Yip,¹ T. Shanahan,³ A. Gundroo,¹ A. Dwivedi,² S. Patel,⁴ M. Zachariah.¹

6:00pm-7:00pm: Pre-Transplant Non-Cytotoxic Donor Specific HLA Antibodies Do Not Increase the Risk of Graft Dysfunction in Kidney Transplant Recipients with Thymoglobulin and IVIG Induction.

A. Colovai, M. Ajaimi, N. Hayde, L. Kamal, S. Chan, C. Savchik, J. Rocca, E. Akalin.

6:00pm-7:00pm: Preformed HLA Donor-Specific Antibodies Disappearance After Kidney Transplantation: Significance and Comparison with Persistent DSA.

D. Redondo,¹ M. Pérez-Sáez,¹ M. Mir,¹ J. Gimeno,¹ C. García,² J. Hernández,² J. Yélamos,³ J. Pascual,¹ M. Crespo.¹

6:00pm-7:00pm: Prospective Monitoring of De Novo Donor-Specific Antibodies: Incidence, Clinical Outcomes and Dynamic Changes Over 5 Years After Kidney Transplantation.

M. Ajaimy, A. Colovai, N. Hayde, J. Graham, M. Lubetzky, L. Kamal, G. De Bocardo, E. Akalin.

6:00pm-7:00pm: Retrospective Analysis of Kidney Transplant Recipients with Antibody-Mediated Rejection.

G. Piñeiro,¹ E. Desousa,¹ J. Villarreal,¹ M. Lozano,² J. Cid,² M. Sole,³ F. Oppenheimer,¹ F. Diekmann.¹

6:00pm-7:00pm: Risk of Kidney Rejection Following Simultaneous Liver Kidney Transplantation.

S. Shah,¹ A. Suddle,¹ V. Aluvihare,¹ O. Shaw,³ C. Shaw,¹ N. Mamode,² C. Callaghan,² G. Koffman,² N. Heaton.¹

6:00pm-7:00pm: Second-Line Therapy After Standard of Care in Antibody-Mediated Rejection: A Prospective Study.

D. Viglietti, A. Loupy, O. Aubert, E. Pillebout, C. Legendre, D. Glotz, C. Lefaucheur.

6:00pm-7:00pm: Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).

B.-H. Shin,¹ M. Everly,² J. Choi,¹ S. Ge,¹ A. Petrosyan,¹ A. Vo,¹ S. Jordan,¹ M. Toyoda.¹

6:00pm-7:00pm: Transcript Changes Associated with Graft Rejection Are Not Specific for Rejection Because They Are Shared with Tissue Responses to Wounding.

P. Halloran, K. Famulski, INTERCOMEX Study Group.

« View all sessions from the 2017 American Transplant Congress